Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.
By P. Marcellin, Ting Chang, S. Lim, M. Tong, W. Sievert, M. Shiffman, L. Jeffers, Z. Goodman, M. Wulfsohn, S. Xiong and 2 more. New England Journal of Medicine, 2003
1,365 citations recorded by the source corpus.
Subfields: Epidemiology, Hepatology, Infectious Diseases
View Paper: https://www.semanticscholar.org/paper/eed955a4cde976a1017d262499533d2a0e752d24
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Epidemiology
In Hepatology
Citations in the corpus
- EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. (2012, background): “Pre-treatment factors In HBeAg-positive CHB, pre-treatment factors predictive of anti-HBe seroconversion are low viral load (HBV DNA below 2 10(8) IU/ml), high serum ALT levels, high activity scores on liver biopsy [69,70,77,116] (A1).”
- Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. (2005, neutral): “(%) 27 (10) 42 (15) 50 (18) 62 (23) 56 (21) 28 (10)”
- Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. (2004, background): “To gain insight on the persistence of cccDNA and clearance mechanisms, we studied patients in different phases of the natural history of CH-B and a group of patients participating in a placebo-controlled trial of the recently approved nucleotide analog adefovir dipivoxil (ADV) 16,17 .”
- Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. (2005, background): “atitis B virus infection, renal failure rates appear low [183, 184].”